Letifend

Authorised

This medicine is authorised for use in the European Union

canine leishmaniasis vaccine (recombinant protein)

Overview

Up-to-date information on this veterinary medicinal product is available on the Veterinary Medicines Information website

Letifend : EPAR - Summary for the public

Product information

Letifend : EPAR - Product Information

Letifend : EPAR - All Authorised presentations

Product details

• Name of medicine:
  Letifend
• Active substance:
  recombinant protein Q from Leishmania infantum MON-1
• International non-proprietary name (INN) or common name:
  canine leishmaniasis vaccine (recombinant protein)

Pharmacotherapeutic group

Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)

Authorisation details

• EMA product number:
  EMEA/V/C/003865

Assessment history

Changes since initial authorisation of medicine

Letifend : EPAR - Procedural steps taken and scientific information after authorisation

Initial marketing authorisation documents

Letifend : EPAR - Public assessment report

Adopted Reference Number: EMA/142471/2016

CVMP summary of positive opinion for Letifend

Adopted Reference Number: EMA/CVMP/4233/2016